financetom
Business
financetom
/
Business
/
Stellantis Promotes Executive to Chief Financial Officer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis Promotes Executive to Chief Financial Officer
Sep 29, 2025 4:02 AM

06:35 AM EDT, 09/29/2025 (MT Newswires) -- Stellantis ( STLA ) said Monday it promoted Joao Laranjo to the automaker's top finance role, succeeding Doug Ostermann, effective immediately.

Laranjo returned to the Chrysler, Fiat and Jeep manufacturer earlier this year as chief financial officer of the company's North America operations. Last year, he served as vice president of finance at Goodyear Tire & Rubber (GT).

"I am pleased to welcome (Laranjo) to the Stellantis ( STLA ) leadership team as we continue to position our company for future growth and long-term success." Chief Executive Antonio Filosa said in a statement.

Ostermann, who was appointed as Stellantis' ( STLA ) CFO in October 2024 as part of a senior management shuffle, will leave the company due to personal reasons.

Stellantis' ( STLA ) New York Stock Exchange-listed shares ticked up 1% in the most recent premarket activity.

In May, the automaker appointed Filosa as its new CEO, effective June 23. Filosa, who previously served as the company's chief operating officer of the Americas, took over from Carlos Tavares, who resigned in December.

Additionally, Stellantis ( STLA ) said its full-year 2025 outlook issued in July remains unchanged. At the time, the company said it expects revenue in the second half to increase sequentially from the first half, and estimates tariffs to have a net impact of about 1.5 billion euros ($1.76 billion) in the year, out of which 300 million euros were incurred in the first half.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia
Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia
Dec 16, 2024
08:52 AM EST, 12/16/2024 (MT Newswires) -- Reviva Pharmaceuticals ( RVPH ) said Monday that preliminary topline data from a phase 3 study of brilaroxazine in patients with schizophrenia was positive as it demonstrated robust broad-spectrum efficacy that was sustained for more than one year. The biopharmaceutical company also said brilaroxazine was generally well tolerated with no single side effect...
EXPLAINER-Everything you need to know about the 2025 Super Bowl 
EXPLAINER-Everything you need to know about the 2025 Super Bowl 
Dec 16, 2024
(Changes headline. No changes to text) Dec 16 (Reuters) - The NFL season is in its home stretch, and with the playoff picture becoming more clear fans are sizing up their team's prospects for making it to the Super Bowl, arguably the biggest single event in U.S. sports with a huge global audience. Here's everything you need to know about...
PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall
PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall
Dec 16, 2024
08:53 AM EST, 12/16/2024 (MT Newswires) -- PepGen ( PEPG ) said Monday it has received a Food and Drug Administration clinical hold notice for its investigational new drug application to initiate a phase 2 trial of PGN-EDO51, a potential treatment for Duchenne muscular dystrophy. The regulator will send an official clinical hold letter within 30 days, the company said....
Carlyle agrees to sell Italy's Forgital to Stonepeak
Carlyle agrees to sell Italy's Forgital to Stonepeak
Dec 16, 2024
MILAN, Dec 16 (Reuters) - Private equity firm Carlyle has agreed to sell Italian firm Forgital, which manufactures forged components mainly for the aerospace sector, to U.S. alternative investment firm Stonepeak, the two companies said on Monday. The deal gives the Italian company an enterprise value of around 2 billion euros ($2.10 billion), a source close to the matter told...
Copyright 2023-2026 - www.financetom.com All Rights Reserved